Cerus Q4 revenue beats expectations

Cerus

02/03/2026 21:08

Corrects Q4 net income metric in Key Details table to -$2.20 mln, from $2.20 mln

Overview

Blood safety firm's Q4 revenue beat analyst expectations

Company entered group purchasing agreement with Blood Centers of America during Q4

Outlook

Cerus expects 2026 product revenue between $224 mln and $228 mln

Company sees 2026 IFC revenue growing 20% to 30%

Cerus aims to improve global access to INTERCEPT technologies

Result Drivers

IFC DEMAND - Fourth-quarter IFC demand increased over 50% year-over-year, contributing to revenue growth

EMEA PERFORMANCE - Strong EMEA performance in the platelets franchise and rollout of INT200 drove Q4 revenue growth

Company press release: ID:nBw1xnqWfa

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
Beat
$64.60 mln
$58.08 mln (4 Analysts)
Q4 EPS
-$0.01
Q4 Net Income
-$2.20 mln
Q4 Adjusted EBITDA
Miss
$3.40 mln
$5.40 mln (2 Analysts)
Q4 Gross Margin
51.50%
Q4 Gross Profit
$29.70 mln
Q4 Operating Expenses
$37.20 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for Cerus Corp is $5.00, about 95.3% above its February 27 closing price of $2.56

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)